4 oktober 2023: dagelijks aspirinegebruik wordt afgeraden op basis van deze meta-analyse uit 2021 want blijkt toch niet echt vormen van kanker te kunnen voorkomen:
Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials
Abstract onderaan dit artikel
14 november 2018: Bron: BMC Cancer. 2018; 18: 288. Published online 2018 Mar 13.
Al heel lang wordt onderzocht wat aspirinegebruik doet bij kanker. Werkt het preventief? Voorkomt het een recidief? Wat zijn de bijwerkingen en gevaren van langdurig aspirinegebruik?
Hier hebben we een aantal studiepublicaties bij elkaar gebracht in een overzicht, zie ook bij darmkanker - preventie in gerelateerde artikelen. Of in gerelateerde artikelen bij dit artikel (tekst gaat verder onder beeld)
Maar raadpleeg ook deze reviewstudie / meta analyse:
Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
De belangrijkste resultaten uit 218 artikelen uit de periode tussen 1985 en 2016 zijn samengevat in grafieken uitgesplitst naar vorm van kanker.
Klik op de grafieken voor de resultaten en studies per vorm van kanker: 1, ,2,2, ,3,3, ,4,4, ,5,5, ,6,6, ,7,7, ,8,8, ,9,9, ,10,10, ,11,11, ,12,12, ,13,13, ,14,14, ,15,15, ,16,16, ,17,17, ,18,18, ,19,19, ,2020 en and21.21.
Deze studie omvatte in totaal 161 cohortstudies en 148 case-control studies. Onder hen zijn 135 studies uitgevoerd in Noord-Amerika, 12 in Azië, 61 in Europa, 8 in Oceanië en 2 in meerdere landen. Over het algemeen was de samengevatte RR 0.89 (95% CI: 0.87-0.91), wat wijst op een verminderd risico op kanker geassocieerd met het gebruik van aspirine. De gecombineerde RR's waren 0,82 (95% CI: 0,79-0,85) voor de case-control studies en 0,94 (95% CI: 0,92-0,97) voor de cohortstudies.
Samenvattend lijkt langdurig aspirinegebruik dus verschillende vormen van kanker te kunnen voorkomen.
Genoemd worden maagkanker, darmkanker, slokdarmkanker, borstkanker, alvleesklierkanker, eierstokkanker, endometriosekanker (buikvlieskanker), prostaatkanker en neuro endocriene tumoren in de spijsverteringskanalen
maar er wordt ook gewaarschuwd voor de gevaren en bijwerkingen. O.a. is een van de gevaren dat inwendige bloedingen door langdurig aspirinegebruik kunnen ontstaan.
Hier de originele conclusie van deze meta-analyse met onderaan artikel het abstract en referentielijst. .
Evidence from observational studies indicates that utilization of aspirin is associated with reduced risk of gastric, colorectal, esophageal, pancreatic, ovarian, endometrial, breast, and prostate cancers, in addition to small intestine neuroendocrine tumors. A stronger protective effect was observed in the North American populations and patients who used aspirin for at least 5 years. It is important to address immortal time bias not only to ensure the integrity of the meta-analysis, but also to ensure the integrity of pharmacoepidemiological studies. Moreover, given the confidence limits of the evaluated studies, adequately powered mechanistic studies should help elucidate the mechanisms underlying this correlation.
Hier het abstract plus referentielijst:
These findings suggest that aspirin use is associated with a reduced risk of gastric, esophageal, colorectal, pancreatic, ovarian, endometrial, breast, and prostate cancers, and small intestine neuroendocrine tumors.
BMC Cancer. 2018; 18: 288.
Published online 2018 Mar 13. doi: [10.1186/s12885-018-4156-5]
PMCID: PMC5851082
PMID: 29534696
Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
1 and This article has been cited by other articles in PMC.
Abstract
Background
Epidemiological studies have clarified the potential associations between regular aspirin use and cancers. However, it remains controversial on whether aspirin use decreases the risk of cancers risks. Therefore, we conducted an updated meta-analysis to assess the associations between aspirin use and cancers.
Methods
The PubMed, Embase, and Web of Science databases were systematically searched up to March 2017 to identify relevant studies. Relative risks (RRs) with 95% confidence intervals (CIs) were used to assess the strength of associations.
Results
A total of 218 studies with 309 reports were eligible for this meta-analysis. Aspirin use was associated with a significant decrease in the risk of overall cancer (RR = 0.89, 95% CI: 0.87–0.91), and gastric (RR = 0.75, 95% CI: 0.65–0.86), esophageal (RR = 0.75, 95% CI: 0.62–0.89), colorectal (RR = 0.79, 95% CI: 0.74–0.85), pancreatic (RR = 0.80, 95% CI: 0.68–0.93), ovarian (RR = 0.89, 95% CI: 0.83–0.95), endometrial (RR = 0.92, 95% CI: 0.85–0.99), breast (RR = 0.92, 95% CI: 0.88–0.96), and prostate (RR = 0.94, 95% CI: 0.90–0.99) cancers, as well as small intestine neuroendocrine tumors (RR = 0.17, 95% CI: 0.05–0.58).
Conclusions
These findings suggest that aspirin use is associated with a reduced risk of gastric, esophageal, colorectal, pancreatic, ovarian, endometrial, breast, and prostate cancers, and small intestine neuroendocrine tumors.
Electronic supplementary material
The online version of this article (10.1186/s12885-018-4156-5) contains supplementary material, which is available to authorized users.
References:
References
1. Oldenburg NC, Duval S, Luepker RV, et al. A 16-month community-based intervention to increase aspirin use for primary prevention of cardiovascular disease. Prev Chronic Dis. 2014;11:E83. doi: 10.5888/pcd11.130378. [PMC free article] [PubMed] [CrossRef]
2. Rainsford KD. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3–27. doi: 10.1007/1-4020-5688-5_1. [PubMed] [CrossRef]
3. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403–407. doi: 10.1016/j.amepre.2007.01.010. [PubMed] [CrossRef]
4. Rodondi N, Cornuz J, Marques-Vidal P, et al. Aspirin use for the primary prevention of coronary heart disease: a population-based study in Switzerland. Prev Med. 2008;46:137–144. doi: 10.1016/j.ypmed.2007.08.006. [PubMed] [CrossRef]
5. VanWormer JJ, Greenlee RT, McBride PE, et al. Aspirin for primary prevention of CVD: are the right people using it? J Fam Pract. 2012;61:525–533. [PubMed]
6. Gilles M, Skyring A. Gastric ulcer, duodenal ulcer and gastric carcinoma: a case-control study of certain social and environmental factors. Med J Aust. 1968;2:1132–1136. [PubMed]
7. Oleske D, Golomb HM, Farber MD, Levy PS. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol. 1985;121:675–683. doi: 10.1093/aje/121.5.675. [PubMed] [CrossRef]
8. Cao Y, Nishihara R, Wu K, et al. Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncol. 2016;2:762–769. doi: 10.1001/jamaoncol.2015.6396. [PMC free article] [PubMed] [CrossRef]
9. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med. 2013;159:77–85. doi: 10.7326/0003-4819-159-2-201307160-00002. [PMC free article] [PubMed] [CrossRef]
10. Zhong S, Chen L, Zhang X, Yu D, Tang J, Zhao J. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. Cancer Epidemiol Biomark Prev. 2015;24:1645–1655. doi: 10.1158/1055-9965.EPI-15-0452. [PubMed] [CrossRef]
11. Cui XJ, He Q, Zhang JM, Fan HJ, Wen ZF, Qin YR. High-dose aspirin consumption contributes to decreased risk for pancreatic cancer in a systematic review and meta-analysis. Pancreas. 2014;43:135–140. doi: 10.1097/MPA.0b013e3182a8d41f. [PubMed] [CrossRef]
12. Oh SW, Myung SK, Park JY, Lee CM, Kwon HT. Aspirin use and risk for lung cancer: a meta-analysis. Ann Oncol. 2011;22:2456–2465. doi: 10.1093/annonc/mdq779. [PubMed] [CrossRef]
13. Huang TB, Yan Y, Guo ZF, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol. 2014;46(9):1715–1728. doi: 10.1007/s11255-014-0703-4. [PubMed] [CrossRef]
14. Zhang YP, Wan YD, Sun YL, Li J, Zhu RT. Aspirin might reduce the incidence of pancreatic cancer: a meta-analysis of observational studies. Sci Rep. 2015;5:15460. doi: 10.1038/srep15460. [PMC free article] [PubMed] [CrossRef]
15. Muranushi C, Olsen CM, Pandeya N, Green AC. Aspirin and nonsteroidal anti-inflammatory drugs can prevent cutaneous squamous cell carcinoma: a systematic review and meta-analysis. J Invest Dermatol. 2015;135:975–983. doi: 10.1038/jid.2014.531. [PubMed] [CrossRef]
16. Sivarasan N, Smith G. Role of aspirin in chemoprevention of esophageal adenocarcinoma: a meta-analysis. J Dig Dis. 2013;14:222–230. doi: 10.1111/1751-2980.12047. [PubMed] [CrossRef]
17. Zhang D, Bai B, Xi Y, Wang T, Zhao Y. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Gynecol Oncol. 2016;142:368–377. doi: 10.1016/j.ygyno.2016.04.543. [PubMed] [CrossRef]
18. Yang P, Zhou Y, Chen B, et al. Aspirin use and the risk of gastric cancer: a meta-analysis. Dig Dis Sci. 2010;55:1533–1539. doi: 10.1007/s10620-009-0915-0. [PubMed] [CrossRef]
19. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283:2008–2012. doi: 10.1001/jama.283.15.2008. [PubMed] [CrossRef]
20. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Canada: Hospital Research Institute, Inc.; 2009.
21. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30. doi: 10.1093/oxfordjournals.epirev.a036298. [PubMed] [CrossRef]
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. doi: 10.1136/bmj.327.7414.557. [PMC free article] [PubMed] [CrossRef]
23. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167(4):492–499. doi: 10.1093/aje/kwm324. [PubMed] [CrossRef]
24. Chan SS, Luben R, Bergmann MM, Boeing H, Olsen A, Tjonneland A, Overvad K, Kaaks R, Kennedy H, Khaw KT, Riboli E, Hart AR. Aspirin in the aetiology of Crohn's disease and ulcerative colitis:a European prospective cohort study. Aliment Pharmacol Ther. 2011;34(6):649–655. doi: 10.1111/j.1365-2036.2011.04784.x. [PubMed] [CrossRef]
25. Velayos FS, Loftus EV, Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130(7):1941–1949. doi: 10.1053/j.gastro.2006.03.028. [PubMed] [CrossRef]
26. Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 2005;6(12):945–952. doi: 10.1016/S1470-2045(05)70431-9. [PubMed] [CrossRef]
27. Masclee GM, Coloma PM, Spaander MC, Kuipers EJ, Sturkenboom MC. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study. BMJ Open. 2015;5(1):e006640. doi: 10.1136/bmjopen-2014-006640. [PMC free article] [PubMed] [CrossRef]
28. Beales IL, Vardi I, Dearman L. Regular statin and aspirin use in patients with Barrett's oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol. 2012;24(8):917–923. doi: 10.1097/MEG.0b013e3283543f01. [PubMed] [CrossRef]
29. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007;58:239–252. doi: 10.1146/annurev.med.57.121304.131253. [PubMed] [CrossRef]
30. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215:1–20. doi: 10.1016/j.canlet.2004.06.014. [PubMed] [CrossRef]
31. Jana NR. NSAIDs and apoptosis. Cell Mol Life Sci. 2008;65:1295–1301. doi: 10.1007/s00018-008-7511-x. [PubMed] [CrossRef]
32. Hung WC. Anti-metastatic action of non-steroidal anti-inflammatory drugs. Kaohsiung J Med Sci. 2008;24:392–397. doi: 10.1016/S1607-551X(08)70162-1. [PubMed] [CrossRef]
33. Stark LA, Reid K, Sansom OJ, et al. Aspirin activates the NF-kappa B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer. Carcinogenesis. 2007;28:968–976. doi: 10.1093/carcin/bgl220. [PubMed] [CrossRef]
34. Din FV, Dunlop MG, Stark LA. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis. Br J Cancer. 2004;91:381–388. doi: 10.1038/sj.bjc.6601913. [PMC free article] [PubMed] [CrossRef]
35. Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A. 1998;95:11301–11306. doi: 10.1073/pnas.95.19.11301. [PMC free article] [PubMed] [CrossRef]
36. Tewari D, Majumdar D, Vallabhaneni S, Bera AK. Aspirin induces cell death by directly modulating mitochondrial voltage-dependent anion channel (VDAC) Sci Rep. 2017;7:45184. doi: 10.1038/srep45184. [PMC free article] [PubMed] [CrossRef]
37. Dore M. Cyclooxygenase-2 expression in animal cancers. Vet Pathol. 2011;48:254–265. doi: 10.1177/0300985810379434. [PubMed] [CrossRef]
38. Zumwalt TJ, Wodarz D, Komarova NL, et al. Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells. Cancer Prev Res (Phila) 2017;10:208–218. doi: 10.1158/1940-6207.CAPR-16-0175. [PMC free article] [PubMed] [CrossRef]
39. Ye X, Fu J, Yang Y, Chen S. Dose-risk and duration-risk relationships between aspirin and colorectal cancer: a meta-analysis of published cohort studies. PLoS One. 2013;8:e57578. doi: 10.1371/journal.pone.0057578. [PMC free article] [PubMed] [CrossRef]
40. Huang XZ, Chen Y, Wu J, et al. Aspirin and non-steroidal anti-inflammatory drugs use reduce gastric cancer risk: a dose-response meta-analysis. Oncotarget. 2017;8:4781–4795. [PMC free article] [PubMed]
41. Egan KM, Nabors LB, Thompson ZJ, et al. Analgesic use and the risk of primary adult brain tumor. Eur J Epidemiol. 2016;31:917–925. doi: 10.1007/s10654-016-0129-7. [PMC free article] [PubMed] [CrossRef]
42. Chubak J, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DS, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. preventive services task force. Ann Intern Med. 2016;164:814–825. doi: 10.7326/M15-2117. [PubMed] [CrossRef]
43. Chubak J, Kamineni A, Buist DSM, Anderson ML, EP W. Aspirin use for the prevention of colorectal cancer: an updated systematic evidence review for the U.S. preventive services task force. US: Agency for Healthcare Research and Quality, Inc.; 2015. [PubMed]
44. Garcia Rodriguez LA, Gonzalez PA. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomark Prev. 2004;13:649–653. [PubMed]
45. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23:1403–1415. doi: 10.1093/annonc/mds113. [PubMed] [CrossRef]
46. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518–527. doi: 10.1016/S1470-2045(12)70112-2. [PubMed] [CrossRef]
47. Iqbal U, Yang HC, Jian WS, Yen Y, Li YJ. Does aspirin use reduce the risk for cancer? J Investig Med. 2017;65(2):391–392. doi: 10.1136/jim-2016-000275. [PubMed] [CrossRef]
48. Wang Y, Shen C, Ge J, Duan H. Regular aspirin use and stomach cancer risk in China. Eur J Surg Oncol. 2015;41(6):801–804. doi: 10.1016/j.ejso.2015.02.006. [PubMed] [CrossRef]
49. Gong EJ, Ahn JY, Jung HY, Lim H, Choi KS, Lee JH, Kim DH, Choi KD, Song HJ, Lee GH, et al. Risk factors and clinical outcomes of gastric cancer identified by screening endoscopy: a case-control study. J Gastroenterol Hepatol. 2014;29(2):301–309. doi: 10.1111/jgh.12387. [PubMed] [CrossRef]
50. Bertuccio P, Bravi F, Bosetti C, Negri E, La Vecchia C. Aspirin and gastric cancer risk. Eur J Cancer Prev. 2010;19(6):426–427. doi: 10.1097/CEJ.0b013e32833ecbdc. [PubMed] [CrossRef]
51. Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, et al. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes Control. 2009;20(3):361–368. doi: 10.1007/s10552-008-9250-6. [PMC free article] [PubMed] [CrossRef]
52. Duan L, Wu AH, Sullivan-Halley J, Bernstein L. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomark Prev. 2008;17(1):126–134. doi: 10.1158/1055-9965.EPI-07-0664. [PubMed] [CrossRef]
53. Fortuny J, Johnson CC, Bohlke K, Chow WH, Hart G, Kucera G, Mujumdar U, Ownby D, Wells K, Yood MU, et al. Use of anti-inflammatory drugs and lower esophageal sphincter-relaxing drugs and risk of esophageal and gastric cancers. Clin Gastroenterol Hepatol. 2007;5(10):1154–1159. doi: 10.1016/j.cgh.2007.05.022. [PMC free article] [PubMed] [CrossRef]
54. Akre K, Ekstrom AM, Signorello LB, Hansson LE, Nyren O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer. 2001;84(7):965–968. doi: 10.1054/bjoc.2001.1702. [PMC free article] [PubMed] [CrossRef]
55. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomark Prev. 2000;9(1):119–123. [PubMed]
56. Zaridze D, Borisova E, Maximovitch D, Chkhikvadze V. Aspirin protects against gastric cancer: results of a case-control study from Moscow, Russia. Int J Cancer. 1999;82(4):473–476. doi: 10.1002/(SICI)1097-0215(19990812)82:4<473::AID-IJC1>3.0.CO;2-K. [PubMed] [CrossRef]
57. Kim YI, Kim SY, Kim JH, Lee JH, Kim YW, Ryu KW, Park JH, Choi IJ. Long-term low-dose aspirin use reduces gastric cancer incidence: a Nationwide cohort study. Cancer Res Treat. 2016;48(2):798–805. doi: 10.4143/crt.2015.117. [PMC free article] [PubMed] [CrossRef]
58. Lee J, Lee SH, Hur KY, Woo SY, Kim SW, Kang WK. Statins and the risk of gastric cancer in diabetes patients. BMC Cancer. 2012;12:596. doi: 10.1186/1471-2407-12-596. [PMC free article] [PubMed] [CrossRef]
59. Abnet CC, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. Br J Cancer. 2009;100(3):551–557. doi: 10.1038/sj.bjc.6604880. [PMC free article] [PubMed] [CrossRef]
60. Epplein M, Nomura AM, Wilkens LR, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and risk of gastric adenocarcinoma: the multiethnic cohort study. Am J Epidemiol. 2009;170(4):507–514. doi: 10.1093/aje/kwp162. [PMC free article] [PubMed] [CrossRef]
61. Lindblad M, Lagergren J, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomark Prev. 2005;14(2):444–450. doi: 10.1158/1055-9965.EPI-04-0467. [PubMed] [CrossRef]
62. Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88(5):684–688. doi: 10.1038/sj.bjc.6600760. [PMC free article] [PubMed] [CrossRef]
63. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5(2):138–146. doi: 10.1097/00001648-199403000-00003. [PubMed] [CrossRef]
64. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, Study AC. Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidem Biomark Prev. 2008;17(5):1169–1178. doi: 10.1158/1055-9965.EPI-07-2852. [PubMed] [CrossRef]
65. Ranka S, Gee JM, Johnson IT, Skinner J, Hart AR, Rhodes M. Non-steroidal anti-inflammatory drugs, lower oesophageal sphincter-relaxing drugs and oesophageal cancer. A case-control study. Digestion. 2006;74(2):109–115. doi: 10.1159/000097947. [PubMed] [CrossRef]
66. Anderson LA, Johnston BT, Watson RG, Murphy SJ, Ferguson HR, Comber H, McGuigan J, Reynolds JV, Murray LJ. Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res. 2006;66(9):4975–4982. doi: 10.1158/0008-5472.CAN-05-4253. [PubMed] [CrossRef]
67. Jayaprakash V, Menezes RJ, Javle MM, McCann SE, Baker JA, Reid ME, Natarajan N, Moysich KB. Regular aspirin use and esophageal cancer risk. Int J Cancer. 2006;119(1):202–207. doi: 10.1002/ijc.21814. [PubMed] [CrossRef]
68. Sharp L, Chilvers CE, Cheng KK, McKinney PA, Logan RF, Cook-Mozaffari P, Ahmed A, Day NE. Risk factors for squamous cell carcinoma of the oesophagus in women: a case-control study. Br J Cancer. 2001;85(11):1667–1670. doi: 10.1054/bjoc.2001.2147. [PMC free article] [PubMed] [CrossRef]
69. Macfarlane TV, Lefevre K, Watson MC. Aspirin and non-steroidal anti-inflammatory drug use and the risk of upper aerodigestive tract cancer. Br J Cancer. 2014;111(9):1852–1859. doi: 10.1038/bjc.2014.473. [PMC free article] [PubMed] [CrossRef]
70. Friis S, Riis AH, Erichsen R, Baron JA, Sorensen HT. Low-dose aspirin or nonsteroidal anti-inflammatory drug use and colorectal cancer risk: a population-based, case-control study. Ann Intern Med. 2015;163(5):347–355. doi: 10.7326/M15-0039. [PubMed] [CrossRef]
71. Rennert G, Rennert HS, Pinchev M, Gruber SB. A case-control study of levothyroxine and the risk of colorectal cancer. J Natl Cancer Inst. 2010;102(8):568–572. doi: 10.1093/jnci/djq042. [PMC free article] [PubMed] [CrossRef]
72. Din FVN, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, Stark L, Porteous ME, Campbell H, Dunlop MG. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59(12):1670–U1114. doi: 10.1136/gut.2009.203000. [PubMed] [CrossRef]
73. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2008;8:237. doi: 10.1186/1471-2407-8-237. [PMC free article] [PubMed] [CrossRef]
74. Kim S, Martin C, Galanko J, Woosley JT, Schroeder JC, Keku TO, Satia JA, Halabi S, Sandler RS. Use of nonsteroidal Antiinflammatory drugs and distal large bowel cancer in whites and African Americans. Am J Epidemiol. 2008;168(11):1292–1300. doi: 10.1093/aje/kwn255. [PMC free article] [PubMed] [CrossRef]
75. Hoffmeister M, Chang-Claude J, Brenner H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int J Cancer. 2007;121(6):1325–1330. doi: 10.1002/ijc.22796. [PubMed] [CrossRef]
76. Slattery ML, Curtin K, Wolff R, Ma KN, Sweeney C, Murtaugh M, Potter JD, Levin TR, Samowitz W. PPAR gamma and colon and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States) Cancer Causes Control. 2006;17(3):239–249. doi: 10.1007/s10552-005-0411-6. [PubMed] [CrossRef]
77. Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidem Biomark Prev. 2005;14(7):1613–1618. doi: 10.1158/1055-9965.EPI-04-0878. [PubMed] [CrossRef]
78. Juarranz M, Calle-Puron ME, Gonzalez-Navarro A, Regidor-Poyatos E, Soriano T, Martinez-Hernandez D, Rojas VD, Guinee VF. Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur J Cancer Prev. 2002;11(5):465–472. doi: 10.1097/00008469-200210000-00009. [PubMed] [CrossRef]
79. Evans RC, Fear S, Ashby D, Hackett A, Williams E, Van der Vliet M, Dunstan FDJ, Rhodes JM. Diet and colorectal cancer: an investigation of the lectin/galactose hypothesis. Gastroenterology. 2002;122(7):1784–1792. doi: 10.1053/gast.2002.33659. [PubMed] [CrossRef]
80. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, et al. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidem Biomark Prev. 1998;7(10):869–873. [PubMed]
81. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer. 1998;82(12):2326–2333. doi: 10.1002/(SICI)1097-0142(19980615)82:12<2326::AID-CNCR5>3.0.CO;2-Q. [PubMed] [CrossRef]
82. LaVecchia C, Negri E, Franceschi S, Conti E, Montella M, Giacosa A, Falcini F, Decarli A. Aspirin and colorectal cancer. Br J Cancer. 1997;76(5):675–677. doi: 10.1038/bjc.1997.444. [PMC free article] [PubMed] [CrossRef]
83. Reeves MJ, Newcomb PA, Trentham-Dietz A, Storer BE, Remington PL. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomark Prev. 1996;5(12):955–960. [PubMed]
84. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72(4):1171–1177. doi: 10.1002/1097-0142(19930815)72:4<1171::AID-CNCR2820720407>3.0.CO;2-D. [PubMed] [CrossRef]
85. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne colorectal cancer study. Cancer Res. 1988;48(15):4399–4404. [PubMed]
86. Park SY, Wilkens LR, Kolonel LN, Monroe KR, Haiman CA, Marchand LL. Exploring differences in the aspirin-colorectal cancer association by sex and race/ethnicity: the multiethnic cohort study. Cancer Epidemiol Biomark Prev. 2017;26(2):162–169. doi: 10.1158/1055-9965.EPI-16-0560. [PMC free article] [PubMed] [CrossRef]
87. Kim C, Zhang X, Chan AT, Sesso HD, Rifai N, Stampfer MJ, Ma J. Inflammatory biomarkers, aspirin, and risk of colorectal cancer: findings from the physicians’ health study. Cancer Epidemiol. 2016;44:65–70. doi: 10.1016/j.canep.2016.07.012. [PMC free article] [PubMed] [CrossRef]
88. Soriano LC, Soriano-Gabarro M, Rodriguez LAG. The protective effect of low-dose aspirin against colorectal cancer is unlikely explained by selection bias: results from three different study designs in clinical practice. PLoS One. 2016;11(7):e0159179. doi: 10.1371/journal.pone.0159179. [PMC free article] [PubMed] [CrossRef]
89. Vaughan LE, Prizment A, Blair CK, Thomas W, Anderson KE. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women's health study. Cancer Causes Control. 2016;27(11):1395–1402. doi: 10.1007/s10552-016-0804-8. [PMC free article] [PubMed] [CrossRef]
90. Lin CC, Lai MS, Shau WY. Can aspirin reduce the risk of colorectal cancer in people with diabetes? A population-based cohort study. Diabet Med. 2015;32(3):324–331. doi: 10.1111/dme.12596. [PubMed] [CrossRef]
91. Hollestein LM, van Herk-Sukel MPP, Ruiter R, de Vries E, Mathijssen RHJ, Wiemer EAC, Stijnen T, Coebergh JWW, Lemmens VEPP, Herings RMC, et al. Incident cancer risk after the start of aspirin use: results from a Dutch population-based cohort study of low dose aspirin users. Int J Cancer. 2014;135(1):157–165. doi: 10.1002/ijc.28634. [PubMed] [CrossRef]
92. Brasky TM, Liu JM, White E, Peters U, Potter JD, Walter RB, Baik CS, Lane DS, Manson JE, Vitolins MZ, et al. Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health Initiative. Int J Cancer. 2014;135(8):1869–1883. doi: 10.1002/ijc.28823. [PMC free article] [PubMed] [CrossRef]
93. Brasky TM, Potter JD, Kristal AR, Patterson RE, Peters U, Asgari MM, Thornquist MD, White E. Non-steroidal anti-inflammatory drugs and cancer incidence by sex in the VITamins and lifestyle (VITAL) cohort. Cancer Causes Control. 2012;23(3):431–444. doi: 10.1007/s10552-011-9891-8. [PMC free article] [PubMed] [CrossRef]
94. Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106(7):1340–1350. doi: 10.1038/ajg.2011.38. [PMC free article] [PubMed] [CrossRef]
95. Friis S, Poulsen AH, Sorensen HT, Tjonneland A, Overvad K, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: a Danish cohort study. Cancer Causes Control. 2009;20(5):731–740. doi: 10.1007/s10552-008-9286-7. [PubMed] [CrossRef]
96. Siemes C, Visser LE, Coebergh JWW, Hofman A, Uitterfnden AG, Stricker BHC. Protective effect of NSAIDs on cancer and influence of COX-2 C(−765)G genotype. Curr Cancer Drug Targets. 2008;8(8):753–764. doi: 10.2174/156800908786733414. [PubMed] [CrossRef]
97. Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133(2):393–402. doi: 10.1053/j.gastro.2007.05.023. [PubMed] [CrossRef]
98. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608–615. doi: 10.1093/jnci/djk132. [PubMed] [CrossRef]
99. Larsson SC, Giovannucci E, Wolk A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br J Cancer. 2006;95(9):1277–1279. doi: 10.1038/sj.bjc.6603442. [PMC free article] [PubMed] [CrossRef]
100. Muscat JE, Dyer AM, Rosenbaum RE, Rigas B. Nitric oxide-releasing medications and colorectal cancer risk: the Framingham study. Anticancer Res. 2005;25(6c):4471–4474. [PubMed]
101. Rahme E, Barkun AN, Toubouti Y, Bardou M. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence. Gastroenterology. 2003;125(2):404–412. doi: 10.1016/S0016-5085(03)00880-1. [PubMed] [CrossRef]
102. Rodriguez LAG, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12(1):88–93. doi: 10.1097/00001648-200101000-00015. [PubMed] [CrossRef]
103. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299(6710):1247–1250. doi: 10.1136/bmj.299.6710.1247. [PMC free article] [PubMed] [CrossRef]
104. Choi JG, Ghoz HM, Peeraphatdit T, Baichoo E, Addissie BD, Harmsen WS, Therneau TM, Olson JE, Chaiteerakij R, Roberts LR. Aspirin use and the risk of cholangiocarcinoma. Hepatology. 2016;64(3):785–796. doi: 10.1002/hep.28529. [PMC free article] [PubMed] [CrossRef]
105. Yang BY, Petrick JL, Chen J, Hagberg KW, Sahasrabuddhe VV, Graubard BI, Jick S, McGlynn KA. Associations of NSAID and paracetamol use with risk of primary liver cancer in the clinical practice research datalink. Cancer Epidemiol. 2016;43:105–111. doi: 10.1016/j.canep.2016.06.009. [PMC free article] [PubMed] [CrossRef]
106. Burr NE, Talboys RJ, Savva S, Clark A, Phillips M, Metcalfe M, Dennison A, Robinson R, Lewis MP, Rhodes M, et al. Aspirin may prevent cholangiocarcinoma: a case-control study from the United Kingdom. Dig Dis Sci. 2014;59(7):1567–1572. doi: 10.1007/s10620-014-3056-z. [PubMed] [CrossRef]
107. Kim G, Jang SY, Han E, Lee YH, Park SY, Nam CM, Kang ES. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: a nationwide nested case-control study. Int J Cancer. 2017;140(4):798–806. doi: 10.1002/ijc.30506. [PubMed] [CrossRef]
108. Petrick JL, Sahasrabuddhe VV, Chan AT, Alavanja MC, Beane-Freeman LE, Buring JE, Chen J, Chong DQ, Freedman ND, Fuchs CS, et al. NSAID use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the liver cancer pooling project. Cancer Prev Res. 2015;8(12):1156–1162. doi: 10.1158/1940-6207.CAPR-15-0126. [PMC free article] [PubMed] [CrossRef]
109. Liu EJ, Sakoda LC, Gao YT, Rashid A, Shen MC, Wang BS, Deng J, Han TQ, Zhang BH, Fraumeni JF, et al. Aspirin use and risk of biliary tract cancer: a population-based study in shanghai, China. Cancer Epidem Biomark Prev. 2005;14(5):1315–1318. doi: 10.1158/1055-9965.EPI-05-0032. [PubMed] [CrossRef]
110. Risch HA, Lu LG, Streicher SA, Wang J, Zhang W, Ni QX, Kidd MS, Yu H, Gao YT. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidem Biomark Prev. 2017;26(1):68–74. doi: 10.1158/1055-9965.EPI-16-0508. [PMC free article] [PubMed] [CrossRef]
111. Kho PF, Fawcett J, Fritschi L, Risch H, Webb PM, Whiteman DC, Neale RE. Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(12):1457–1464. doi: 10.1007/s10552-016-0824-4. [PubMed] [CrossRef]
112. Streicher SA, Yu H, Lu LG, Kidd MS, Risch HA. Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidem Biomark Prev. 2014;23(7):1254–1263. doi: 10.1158/1055-9965.EPI-13-1284. [PMC free article] [PubMed] [CrossRef]
113. Tan XL, Lombardo KMR, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, Petersen GM. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res. 2011;4(11):1835–1841. doi: 10.1158/1940-6207.CAPR-11-0146. [PMC free article] [PubMed] [CrossRef]
114. Pugh TFG, Little M, Carey F, Metcalfe M, Robinson R, Clark A, Ndokera R, Ing H, Dennison A, Hart A. Aspirin, Nsaids, Calcium-Channel blockers and statins in the Aetiology of pancreatic cancer: preliminary results from a case-control study in two Centres in the Uk. Gut. 2011;60:A81. doi: 10.1136/gut.2011.239301.166. [CrossRef]
115. Bonifazi M, Gallus S, Bosetti C, Polesel J, Serraino D, Talamini R, Negri E, La Vecchia C. Aspirin use and pancreatic cancer risk. Eur J Cancer Prev. 2010;19(5):352–354. doi: 10.1097/CEJ.0b013e32833b48a4. [PubMed] [CrossRef]
116. Menezes RJ, Huber KR, Mahoney MC, Moysich KB. Regular use of aspirin and pancreatic cancer risk. BMC Public Health. 2002;2:18. doi: 10.1186/1471-2458-2-18. [PMC free article] [PubMed] [CrossRef]
117. Bradley MC, Hughes CM, Cantwell MM, Napolitano G, Murray LJ. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2010;102(9):1415–1421. doi: 10.1038/sj.bjc.6605636. [PMC free article] [PubMed] [CrossRef]
118. Anderson KE, Johnson TW, Lazovich D, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002;94(15):1168–1171. doi: 10.1093/jnci/94.15.1168. [PubMed] [CrossRef]
119. Lim WY, Chuah KL, Eng P, Leong SS, Lim E, Lim TK, Ng A, Poh WT, Tee A, Teh M, et al. Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer. Lung Cancer. 2012;77(2):246–251. doi: 10.1016/j.lungcan.2012.03.005. [PubMed] [CrossRef]
120. McCormack VA, Hung RJ, Brenner DR, Bickeboller H, Rosenberger A, Muscat JE, Lazarus P, Tjonneland A, Friis S, Christiani DC, et al. Aspirin and NSAID use and lung cancer risk: a pooled analysis in the international lung cancer consortium (ILCCO) Cancer Causes Control. 2011;22(12):1709–1720. doi: 10.1007/s10552-011-9847-z. [PMC free article] [PubMed] [CrossRef]
121. Kelly JP, Coogan P, Strom BL, Rosenberg L. Lung cancer and regular use of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs. Pharmacoepidem Drug Saf. 2008;17(4):322–327. doi: 10.1002/pds.1532. [PubMed] [CrossRef]
122. Van Dyke AL, Cote ML, Prysak G, Claeys GB, Wenzlaff AS, Schwartz AG. Regular adult aspirin use decreases the risk of non-small cell lung cancer among women. Cancer Epidem Biomark Prev. 2008;17(1):148–157. doi: 10.1158/1055-9965.EPI-07-0517. [PMC free article] [PubMed] [CrossRef]
123. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci. 2007;3(5):328–334. doi: 10.7150/ijbs.3.328. [PMC free article] [PubMed] [CrossRef]
124. Muscat JE, Chen SQ, Richie JP, Jr, Altorki NK, Citron M, Olson S, Neugut AI, Stellman SD. Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs. Cancer. 2003;97(7):1732–1736. doi: 10.1002/cncr.11242. [PubMed] [CrossRef]
125. Moysich KB, Menezes RJ, Ronsani A, Swede H, Reid ME, Cummings KM, Falkner KL, Loewen GM, Bepler G. Regular aspirin use and lung cancer risk. BMC Cancer. 2002;2:31. doi: 10.1186/1471-2407-2-31. [PMC free article] [PubMed] [CrossRef]
126. Baik CS, Brasky TM, Pettinger M, Luo JH, Gong ZH, Wactawski-Wende J, Prentice RL. Nonsteroidal anti-inflammatory drug and aspirin use in relation to lung cancer risk among postmenopausal women. Cancer Epidem Biomark Prev. 2015;24(5):790–797. doi: 10.1158/1055-9965.EPI-14-1322. [PMC free article] [PubMed] [CrossRef]
127. Brasky TM, Baik CS, Slatore CG, Potter JD, White E. Non-steroidal anti-inflammatory drugs and small cell lung cancer risk in the VITAL study. Lung Cancer. 2012;77(2):260–264. doi: 10.1016/j.lungcan.2012.04.015. [PMC free article] [PubMed] [CrossRef]
128. Olsen JH, Friis S, Poulsen AH, Fryzek J, Harving H, Tjonneland A, Sorensen HT, Blot W. Use of NSAIDs, smoking and lung cancer risk. Br J Cancer. 2008;98(1):232–237. doi: 10.1038/sj.bjc.6604151. [PMC free article] [PubMed] [CrossRef]
129. Hernandez-Diaz S, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer. 2007;120(7):1565–1572. doi: 10.1002/ijc.22514. [PubMed] [CrossRef]
130. Hayes JH, Anderson KE, Folsom AR. Association between nonsteroidal anti-inflammatory drug use and the incidence of lung cancer in the Iowa women's health study. Cancer Epidem Biomark Prev. 2006;15(11):2226–2231. doi: 10.1158/1055-9965.EPI-06-0172. [PubMed] [CrossRef]
131. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Koenig KL, Shore RE. Aspirin and lung cancer in women. Br J Cancer. 2002;87(1):49–53. doi: 10.1038/sj.bjc.6600370. [PMC free article] [PubMed] [CrossRef]
132. Dierssen-Sotos T, Gomez-Acebo I, de Pedro M, Perez-Gomez B, Servitja S, Moreno V, Amiano P, Fernandez-Villa T, Barricarte A, Tardon A, et al. Use of non-steroidal anti-inflammatory drugs and risk of breast cancer: the Spanish multi-case-control (MCC) study. BMC Cancer. 2016;16(1):660. doi: 10.1186/s12885-016-2692-4. [PMC free article] [PubMed] [CrossRef]
133. Cui Y, Deming-Halverson SL, Shrubsole MJ, Beeghly-Fadiel A, Cai H, Fair AM, Shu XO, Zheng W. Use of nonsteroidal anti-inflammatory drugs and reduced breast cancer risk among overweight women. Breast Cancer Res Treat. 2014;146(2):439–446. doi: 10.1007/s10549-014-3030-7. [PMC free article] [PubMed] [CrossRef]
134. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Trevisan M, et al. Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the western New York exposures and breast cancer (WEB) study. Cancer Causes Control. 2010;21(9):1503–1512. doi: 10.1007/s10552-010-9579-5. [PMC free article] [PubMed] [CrossRef]
135. Cronin-Fenton DP, Pedersen L, Lash TL, Friis S, Baron JA, Sorensen HT. Prescriptions for selective cyclooxygenase-2 inhibitors, non-selective non-steroidal anti-inflammatory drugs, and risk of breast cancer in a population-based case-control study. Breast Cancer Res. 2010;12(2):R15. doi: 10.1186/bcr2482. [PMC free article] [PubMed] [CrossRef]
136. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomark Prev. 2007;16(4):747–755. doi: 10.1158/1055-9965.EPI-06-0667. [PubMed] [CrossRef]
137. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 2006;6:27. doi: 10.1186/1471-2407-6-27. [PMC free article] [PubMed] [CrossRef]
138. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology. 2005;68(1):40–47. doi: 10.1159/000084818. [PubMed] [CrossRef]
139. Zhang YQ, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the case-control surveillance study revisited. Am J Epidemiol. 2005;162(2):165–170. doi: 10.1093/aje/kwi182. [PubMed] [CrossRef]
140. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291(20):2433–2440. doi: 10.1001/jama.291.20.2433. [PubMed] [CrossRef]
141. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control. 2003;14(10):915–922. doi: 10.1023/B:CACO.0000007973.59863.66. [PubMed] [CrossRef]
142. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidem Biomark Prev. 2001;10(11):1213–1217. [PubMed]
143. Kim S, Shore DL, Wilson LE, Sanniez EI, Kim JH, Taylor JA, Sandler DP. Lifetime use of nonsteroidal anti-inflammatory drugs and breast cancer risk: results from a prospective study of women with a sister with breast cancer. BMC Cancer. 2015;15:960. doi: 10.1186/s12885-015-1979-1. [PMC free article] [PubMed] [CrossRef]
144. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat. 2011;126(1):149–155. doi: 10.1007/s10549-010-1074-x. [PMC free article] [PubMed] [CrossRef]
145. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US black women. Cancer Causes Control. 2011;22(11):1553–1561. doi: 10.1007/s10552-011-9832-6. [PMC free article] [PubMed] [CrossRef]
146. Eliassen AH, Chen WY, Spiegelman D, Willett WC, Hunter DJ, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and risk of breast cancer among premenopausal women in the Nurses’ health study II. Arch Intern Med. 2009;169(2):115–121. doi: 10.1001/archinternmed.2008.537. [PMC free article] [PubMed] [CrossRef]
147. Friis S, Thomassen L, Sorensen HT, Tjonneland A, Overvad K, Cronin-Fenton DR, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev. 2008;17(2):88–96. doi: 10.1097/CEJ.0b013e3282b6fd55. [PubMed] [CrossRef]
148. Gierach GL, Lacey JV, Jr, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the National Institutes of Health-AARP diet and health study. Breast Cancer Res. 2008;10(2):R38. doi: 10.1186/bcr2089. [PMC free article] [PubMed] [CrossRef]
149. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat. 2008;109(3):533–543. doi: 10.1007/s10549-007-9665-x. [PubMed] [CrossRef]
150. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk - the multiethnic cohort. Am J Epidemiol. 2007;166(10):1150–1158. doi: 10.1093/aje/kwm195. [PubMed] [CrossRef]
151. Gallicchio L, Visvanathan K, Burke A, Hoffman SC, Helzlsouer KJ. Nonsteroidal anti-inflammatory drugs and the risk of developing breast cancer in a population-based prospective cohort study in Washington County, MD. Int J Cancer. 2007;121(1):211–215. doi: 10.1002/ijc.22656. [PubMed] [CrossRef]
152. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn-Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, et al. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst. 2005;97(11):805–812. doi: 10.1093/jnci/dji140. [PubMed] [CrossRef]
153. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer. 2005;5:159. doi: 10.1186/1471-2407-5-159. [PMC free article] [PubMed] [CrossRef]
154. Rodriguez LAG, Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other antiinflammatory drugs. Br J Cancer. 2004;91(3):525–529. doi: 10.1038/sj.bjc.6602003. [PMC free article] [PubMed] [CrossRef]
155. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep. 1999;6(1):71–73. [PubMed]
156. Peres LC, Camacho F, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Crankshaw S, Funkhouser E, et al. Analgesic medication use and risk of epithelial ovarian cancer in African American women. Br J Cancer. 2016;114(7):819–825. doi: 10.1038/bjc.2016.39. [PMC free article] [PubMed] [CrossRef]
157. Baandrup L. Drugs with potential chemopreventive properties in relation to epithelial ovarian cancer--a nationwide case-control study. Dan Med J. 2015;62(7). [PubMed]
158. Lo-Ciganic WH, Zgibor JC, Bunker CH, Moysich KB, Edwards RP, Ness RB. Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, or acetaminophen and risk of ovarian cancer. Epidemiology. 2012;23(2):311–319. doi: 10.1097/EDE.0b013e3182456ad3. [PMC free article] [PubMed] [CrossRef]
159. Ammundsen HB, Faber MT, Jensen A, Hogdall E, Blaakaer J, Hogdall C, Kjaer SK. Use of analgesic drugs and risk of ovarian cancer: results from a Danish case-control study. Acta Obstet Gynecol Scand. 2012;91(9):1094–1102. doi: 10.1111/j.1600-0412.2012.01472.x. [PubMed] [CrossRef]
160. Pinheiro SP, Gates MA, De Vivo I, Rosner BA, Tworoger SS, Titus-Ernstoff L, Hankinson SE, Cramer DW. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet. 2010;1(4):320–331. [PMC free article] [PubMed]
161. Wu AH, Pearce CL, Tseng CC, Templeman C, Pike MC. Markers of inflammation and risk of ovarian cancer in Los Angeles County. Int J Cancer. 2009;124(6):1409–1415. doi: 10.1002/ijc.24091. [PMC free article] [PubMed] [CrossRef]
162. Wernli KJ, Newcomb PA, Hampton JM, Trentham-Dietz A, Egan KM. Inverse association of NSAID use and ovarian cancer in relation to oral contraceptive use and parity. Br J Cancer. 2008;98(11):1781–1783. doi: 10.1038/sj.bjc.6604392. [PMC free article] [PubMed] [CrossRef]
163. Merritt MA, Green AC, Nagle CM, Webb PM, Australian Cancer S. Australian Ovarian Cancer Study G Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer. 2008;122(1):170–176. doi: 10.1002/ijc.23017. [PubMed] [CrossRef]
164. Schildkraut JM, Moorman PG, Halabi S, Calingaert B, Marks JR, Berchuck A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17(1):104–107. doi: 10.1097/01.ede.0000190538.55645.f8. [PubMed] [CrossRef]
165. Moysich KB, Mettlin C, Piver MS, Natarajan N, Menezes RJ, Swede H. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomark Prev. 2001;10(8):903–906. [PubMed]
166. Rosenberg L, Palmer JR, Rao RS, Coogan PF, Strom BL, Zauber AG, Stolley PD, Shapiro S. A case-control study of analgesic use and ovarian cancer. Cancer Epidemiol Biomark Prev. 2000;9(9):933–937. [PubMed]
167. Tavani A, Gallus S, La Vecchia C, Conti E, Montella M, Franceschi S. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol. 2000;11(9):1171–1173. doi: 10.1023/A:1008373616424. [PubMed] [CrossRef]
168. Cramer DW, Harlow BL, Titus-Ernstoff L, Bohlke K, Welch WR, Greenberg ER. Over-the-counter analgesics and risk of ovarian cancer. Lancet. 1998;351(9096):104–107. doi: 10.1016/S0140-6736(97)08064-1. [PubMed] [CrossRef]
169. Setiawan VW, Matsuno RK, Lurie G, Wilkens LR, Carney ME, Henderson BE, Kolonel LN, Goodman MT. Use of nonsteroidal anti-inflammatory drugs and risk of ovarian and endometrial cancer: the multiethnic cohort. Cancer Epidemiol Biomark Prev. 2012;21(9):1441–1449. doi: 10.1158/1055-9965.EPI-12-0390-T. [PMC free article] [PubMed] [CrossRef]
170. Murphy MA, Trabert B, Yang HP, Park Y, Brinton LA, Hartge P, Sherman ME, Hollenbeck A, Wentzensen N. Non-steroidal anti-inflammatory drug use and ovarian cancer risk: findings from the NIH-AARP diet and health study and systematic review. Cancer Causes Control. 2012;23(11):1839–1852. doi: 10.1007/s10552-012-0063-2. [PMC free article] [PubMed] [CrossRef]
171. Prizment AE, Folsom AR, Anderson KE. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women's health study. Cancer Epidemiol Biomark Prev. 2010;19(2):435–442. doi: 10.1158/1055-9965.EPI-09-0976. [PMC free article] [PubMed] [CrossRef]
172. Lacey JV, Sherman ME, Hartge P, Schatzkin A, Schairer C. Medication use and risk of ovarian carcinoma: a prospective study. Int J Cancer. 2004;108(2):281–286. doi: 10.1002/ijc.11538. [PubMed] [CrossRef]
173. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med. 2001;33(6):682–687. doi: 10.1006/pmed.2001.0945. [PubMed] [CrossRef]
174. Brons N, Baandrup L, Dehlendorff C, Kjaer SK. Use of nonsteroidal anti-inflammatory drugs and risk of endometrial cancer: a nationwide case-control study. Cancer Causes Control. 2015;26(7):973–981. doi: 10.1007/s10552-015-0578-4. [PubMed] [CrossRef]
175. Neill AS, Nagle CM, Protani MM, Obermair A, Spurdle AB, Webb PM, Australian National Endometrial Cancer Study G Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. Int J Cancer. 2013;132(5):1146–1155. doi: 10.1002/ijc.27717. [PubMed] [CrossRef]
176. Bosetti C, Bravi F, Talamini R, Montella M, Negri E, La Vecchia C. Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur J Cancer Prev. 2010;19(5):401–403. doi: 10.1097/CEJ.0b013e32833b4871. [PubMed] [CrossRef]
177. Fortuny J, Sima C, Bayuga S, Wilcox H, Pulick K, Faulkner S, Zauber AG, Olson SH. Risk of endometrial cancer in relation to medical conditions and medication use. Cancer Epidemiol Biomark Prev. 2009;18(5):1448–1456. doi: 10.1158/1055-9965.EPI-08-0936. [PMC free article] [PubMed] [CrossRef]
178. Bodelon C, Doherty JA, Chen C, Rossing MA, Weiss NS. Use of nonsteroidal antiinflammatory drugs and risk of endometrial cancer. Am J Epidemiol. 2009;170(12):1512–1517. doi: 10.1093/aje/kwp321. [PMC free article] [PubMed] [CrossRef]
179. Moysich KB, Baker JA, Rodabaugh KJ, Villella JA. Regular analgesic use and risk of endometrial cancer. Cancer Epidemiol Biomark Prev. 2005;14(12):2923–2928. doi: 10.1158/1055-9965.EPI-05-0457. [PubMed] [CrossRef]
180. Brasky TM, Moysich KB, Cohn DE, White E. Non-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins and lifestyle (VITAL) cohort. Gynecol Oncol. 2013;128(1):113–119. doi: 10.1016/j.ygyno.2012.10.005. [PMC free article] [PubMed] [CrossRef]
181. Danforth KN, Gierach GL, Brinton LA, Hollenbeck AR, Katki HA, Leitzmann MF, Schatzkin A, Lacey JV., Jr Nonsteroidal anti-inflammatory drug use and endometrial cancer risk in the NIH-AARP diet and health study. Cancer Prev Res (Phila) 2009;2(5):466–472. doi: 10.1158/1940-6207.CAPR-08-0239. [PMC free article] [PubMed] [CrossRef]
182. Viswanathan AN, Feskanich D, Schernhammer ES, Hankinson SE. Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer. Cancer Res. 2008;68(7):2507–2513. doi: 10.1158/0008-5472.CAN-07-6257. [PMC free article] [PubMed] [CrossRef]
183. Friel G, Liu CS, Kolomeyevskaya NV, Hampras SS, Kruszka B, Schmitt K, Cannioto RA, Lele SB, Odunsi KO, Moysich KB. Aspirin and acetaminophen use and the risk of cervical cancer. J Low Genit Tract Dis. 2015;19(3):189–193. doi: 10.1097/LGT.0000000000000104. [PMC free article] [PubMed] [CrossRef]
184. Wilson JC, O'Rorke MA, Cooper JA, Murray LJ, Hughes CM, Gormley GJ, Anderson LA. Non-steroidal anti-inflammatory drug use and cervical cancer risk: a case-control study using the clinical practice research datalink. Cancer Epidemiol. 2013;37(6):897–904. doi: 10.1016/j.canep.2013.08.010. [PubMed] [CrossRef]
185. Skriver C, Dehlendorff C, Borre M, Brasso K, Sorensen HT, Hallas J, Larsen SB, Tjonneland A, Friis S. Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes Control. 2016;27(9):1067–1079. doi: 10.1007/s10552-016-0785-7. [PubMed] [CrossRef]
186. Veitonmaki T, Tammela TLJ, Auvinen A, Murtola TJ. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013;49(4):938–945. doi: 10.1016/j.ejca.2012.09.030. [PubMed] [CrossRef]
187. Murad AS, Down L, Smith GD, Donovan JL, Lane JA, Hamdy FC, Neal DE, Martin RM. Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study) Int J Cancer. 2011;128(6):1442–1448. doi: 10.1002/ijc.25465. [PubMed] [CrossRef]
188. Salinas CA, Kwon EM, FitzGerald LM, Feng ZD, Nelson PS, Ostrander EA, Peters U, Stanford JL. Use of aspirin and other nonsteroidal Antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010;172(5):578–590. doi: 10.1093/aje/kwq175. [PMC free article] [PubMed] [CrossRef]
189. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem. 2007;42:193–212. doi: 10.1007/1-4020-5688-5_9. [PubMed] [CrossRef]
190. Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C. Aspirin and the risk of prostate cancer. Eur J Cancer Prev. 2006;15(1):43–45. doi: 10.1097/01.cej.0000180665.04335.de. [PubMed] [CrossRef]
191. Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J. 2006;12(2):130–135. [PubMed]
192. Liu X, Plummer SJ, Nock NL, Casey G, Witte JS. Nonsteroidal antiinflammatory drugs and decreased risk of advanced prostate cancer: modification by lymphotoxin alpha. Am J Epidemiol. 2006;164(10):984–989. doi: 10.1093/aje/kwj294. [PubMed] [CrossRef]
193. Menezes RJ, Swede H, Niles R, Moysich KB. Regular use of aspirin and prostate cancer risk (United States) Cancer Causes Control. 2006;17(3):251–256. doi: 10.1007/s10552-005-0450-z. [PubMed] [CrossRef]
194. Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer. 2003;106(3):409–415. doi: 10.1002/ijc.11250. [PubMed] [CrossRef]
195. Norrish AE, Jackson RT, McRae CU. Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998;77(4):511–515. doi: 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X. [PubMed] [CrossRef]
196. Lapi F, Levi M, Simonetti M, Cancian M, Parretti D, Cricelli I, Sobrero A, Cricelli C. Risk of prostate cancer in low-dose aspirin users: a retrospective cohort study. Int J Cancer. 2016;139(1):205–211. doi: 10.1002/ijc.30061. [PubMed] [CrossRef]
197. Nordstrom T, Clements M, Karlsson R, Adolfsson J, Gronberg H. The risk of prostate cancer for men on aspirin, statin or antidiabetic medications. Eur J Cancer. 2015;51(6):725–733. doi: 10.1016/j.ejca.2015.02.003. [PubMed] [CrossRef]
198. Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer. 2012;107(1):207–214. doi: 10.1038/bjc.2012.227. [PMC free article] [PubMed] [CrossRef]
199. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One. 2011;6(1):e16412. doi: 10.1371/journal.pone.0016412. [PMC free article] [PubMed] [CrossRef]
200. Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E. Nonsteroidal anti-inflammatory drugs and prostate cancer risk in the VITamins and lifestyle (VITAL) cohort. Cancer Epidem Biomark Prev. 2010;19(12):3185–3188. doi: 10.1158/1055-9965.EPI-10-0942. [PMC free article] [PubMed] [CrossRef]
201. Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore longitudinal study of aging. Cancer Epidem Biomark Prev. 2005;14(2):390–396. doi: 10.1158/1055-9965.EPI-04-0532. [PubMed] [CrossRef]
202. Habel LA, Zhao W, Stanford JL. Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 2002;13(5):427–434. doi: 10.1023/A:1015788502099. [PubMed] [CrossRef]
203. Karami S, Daughtery SE, Schwartz K, Davis FG, Ruterbusch JJ, Wacholder S, Graubard BI, Berndt SI, Hofmann JN, Purdue MP, et al. Analgesic use and risk of renal cell carcinoma: a case-control, cohort and meta-analytic assessment. Int J Cancer. 2016;139(3):584–592. doi: 10.1002/ijc.30108. [PubMed] [CrossRef]
204. Tavani A, Scotti L, Bosetti C, Dal Maso L, Montella M, Ramazzotti V, Negri E, Franceschi S, La Vecchia C. Aspirin and risk of renal cell cancer in Italy. Eur J Cancer Prev. 2010;19(4):272–274. doi: 10.1097/CEJ.0b013e3283394750. [PubMed] [CrossRef]
205. Gago-Dominguez M, Yuan JM, Castelao JE, Ross RK, Yu MC. Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer. 1999;81(3):542–548. doi: 10.1038/sj.bjc.6690728. [PMC free article] [PubMed] [CrossRef]
206. Chow WH, McLaughlin JK, Linet MS, Niwa S, Mandel JS. Use of analgesics and risk of renal cell cancer. Int J Cancer. 1994;59(4):467–470. doi: 10.1002/ijc.2910590406. [PubMed] [CrossRef]
207. McCredie M, Stewart JH, Day NE. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int J Cancer. 1993;53(2):245–249. doi: 10.1002/ijc.2910530212. [PubMed] [CrossRef]
208. McCredie M, Ford JM, Stewart JH. Risk factors for cancer of the renal parenchyma. Int J Cancer. 1988;42(1):13–16. doi: 10.1002/ijc.2910420104. [PubMed] [CrossRef]
209. Liu W, Park Y, Purdue MP, Giovannucci E, Cho E. A large cohort study of nonsteroidal anti-inflammatory drugs and renal cell carcinoma incidence in the National Institutes of Health-AARP diet and health study. Cancer Causes Control. 2013;24(10):1865–1873. doi: 10.1007/s10552-013-0263-4. [PMC free article] [PubMed] [CrossRef]
210. Cho E, Curhan G, Hankinson SE, Kantoff P, Atkins MB, Stampfer M, Choueiri TK. Prospective evaluation of analgesic use and risk of renal cell cancer. Arch Intern Med. 2011;171(16):1487–1493. doi: 10.1001/archinternmed.2011.356. [PMC free article] [PubMed] [CrossRef]
211. Linet MS, Chow WH, McLaughlin JK, Wacholder S, Yu MC, Schoenberg JB, Lynch C, Fraumeni JF., Jr Analgesics and cancers of the renal pelvis and ureter. Int J Cancer. 1995;62(1):15–18. doi: 10.1002/ijc.2910620105. [PubMed] [CrossRef]
212. Ross RK, Paganini-Hill A, Landolph J, Gerkins V, Henderson BE. Analgesics, cigarette smoking, and other risk factors for cancer of the renal pelvis and ureter. Cancer Res. 1989;49(4):1045–1048. [PubMed]
213. Jensen OM, Knudsen JB, Tomasson H, Sorensen BL. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int J Cancer. 1989;44(6):965–968. doi: 10.1002/ijc.2910440603. [PubMed] [CrossRef]
214. Baris D, Karagas MR, Koutros S, Colt JS, Johnson A, Schwenn M, Fischer AH, Figueroa JD, Berndt SI, Han S, et al. Nonsteroidal anti-inflammatory drugs and other analgesic use and bladder cancer in northern New England. Int J Cancer. 2013;132(1):162–173. doi: 10.1002/ijc.27590. [PMC free article] [PubMed] [CrossRef]
215. Fortuny J, Kogevinas M, Zens MS, Schned A, Andrew AS, Heaney J, Kelsey KT, Karagas MR. Analgesic and anti-inflammatory drug use and risk of bladder cancer: a population based case control study. BMC Urol. 2007;7:13. doi: 10.1186/1471-2490-7-13. [PMC free article] [PubMed] [CrossRef]
216. Fortuny J, Kogevinas M, Garcia-Closas M, Real FX, Tardon A, Garcia-Closas R, Serra C, Carrato A, Lloreta J, Rothman N, et al. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidem Biomark Prev. 2006;15(9):1696–1702. doi: 10.1158/1055-9965.EPI-06-0038. [PubMed] [CrossRef]
217. Castelao JE, Yuan JM, Gago-Dominguez M, Yu MC, Ross RK. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer. 2000;82(7):1364–1369. doi: 10.1054/bjoc.1999.1106. [PMC free article] [PubMed] [CrossRef]
218. Steineck G, Wiholm BE, Gerhardsson de Verdier M. Acetaminophen, some other drugs, some diseases and the risk of transitional cell carcinoma. A population-based case-control study. Acta Oncol. 1995;34(6):741–748. doi: 10.3109/02841869509127181. [PubMed] [CrossRef]
219. Shih C, Hotaling JM, Wright JL, White E. Long-term NSAID use and incident urothelial cell carcinoma in the VITamins and lifestyle (VITAL) study. Urol Oncol. 2013;31(8):1689–1695. doi: 10.1016/j.urolonc.2012.06.001. [PMC free article] [PubMed] [CrossRef]
220. Daugherty SE, Pfeiffer RM, Sigurdson AJ, Hayes RB, Leitzmann M, Schatzkin A, Hollenbeck AR, Silverman DT. Nonsteroidal antiinflammatory drugs and bladder cancer: a pooled analysis. Am J Epidemiol. 2011;173(7):721–730. doi: 10.1093/aje/kwq437. [PMC free article] [PubMed] [CrossRef]
221. Genkinger JM, De Vivo I, Stampfer MJ, Giovannucci E, Michaud DS. Nonsteroidal antiinflammatory drug use and risk of bladder cancer in the health professionals follow-up study. Int J Cancer. 2007;120(10):2221–2225. doi: 10.1002/ijc.22546. [PubMed] [CrossRef]
222. Gaist D, Garcia-Rodriguez LA, Sorensen HT, Hallas J, Friis S. Use of low-dose aspirin and non-aspirin nonsteroidal anti-inflammatory drugs and risk of glioma: a case-control study. Br J Cancer. 2013;108(5):1189–1194. doi: 10.1038/bjc.2013.87. [PMC free article] [PubMed] [CrossRef]
223. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131(6):E1031–E1037. doi: 10.1002/ijc.27536. [PMC free article] [PubMed] [CrossRef]
224. Bannon FJ, O'Rorke MA, Murray LJ, Hughes CM, Gavin AT, Fleming SJ, Cardwell CR. Non-steroidal anti-inflammatory drug use and brain tumour risk: a case-control study within the clinical practice research datalink. Cancer Causes Control. 2013;24(11):2027–2034. doi: 10.1007/s10552-013-0279-9. [PubMed] [CrossRef]
225. Daugherty SE, Moore SC, Pfeiffer RM, Inskip PD, Park Y, Hollenbeck A, Rajaraman P. Nonsteroidal anti-inflammatory drugs and glioma in the NIH-AARP diet and health study cohort. Cancer Prev Res (Phila) 2011;4(12):2027–2034. doi: 10.1158/1940-6207.CAPR-11-0274. [PMC free article] [PubMed] [CrossRef]
226. Di Maso M, Bosetti C, La Vecchia C, Garavello W, Montella M, Libra M, Serraino D, Polesel J. Regular aspirin use and nasopharyngeal cancer risk: a case-control study in Italy. Cancer Epidemiol. 2015;39(4):545–547. doi: 10.1016/j.canep.2015.04.012. [PubMed] [CrossRef]
227. Becker C, Wilson JC, Jick SS, Meier CR. Non-steroidal anti-inflammatory drugs and the risk of head and neck cancer: a case-control analysis. Int J Cancer. 2015;137(10):2424–2431. doi: 10.1002/ijc.29601. [PubMed] [CrossRef]
228. Macfarlane TV, Macfarlane GJ, Thakker NS, Benhamou S, Bouchardy C, Ahrens W, Pohlabeln H, Lagiou P, Lagiou A, Castellsague X, et al. Role of medical history and medication use in the aetiology of upper aerodigestive tract cancers in Europe: the ARCAGE study. Ann Oncol. 2012;23(4):1053–1060. doi: 10.1093/annonc/mdr335. [PubMed] [CrossRef]
229. Ahmadi N, Goldman R, Seillier-Moiseiwitsch F, Noone AM, Kosti O, Davidson BJ. Decreased risk of squamous cell carcinoma of the head and neck in users of nonsteroidal anti-inflammatory drugs. Int J Otolaryngol. 2010;2010:424161. doi: 10.1155/2010/424161. [PMC free article] [PubMed] [CrossRef]
230. Jayaprakash V, Rigual NR, Moysich KB, Loree TR, Nasca MA, Menezes RJ, Reid ME. Chemoprevention of head and neck cancer with aspirin: a case-control study. Arch Otolaryngol Head Neck Surg. 2006;132(11):1231–1236. doi: 10.1001/archotol.132.11.1231. [PubMed] [CrossRef]
231. Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Goran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta Otolaryngol. 2005;125(12):1327–1336. doi: 10.1080/00016480510012273. [PubMed] [CrossRef]
232. Bosetti C, Talamini R, Franceschi S, Negri E, Garavello W, La Vecchia C. Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer. 2003;88(5):672–674. doi: 10.1038/sj.bjc.6600820. [PMC free article] [PubMed] [CrossRef]
233. Wilson JC, Murray LJ, Hughes CM, Black A, Anderson LA. Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer. Br J Cancer. 2013;108(5):1178–1181. doi: 10.1038/bjc.2013.73. [PMC free article] [PubMed] [CrossRef]
234. Patel D, Kitahara CM, Park Y, Liao LM, Linet M, Kebebew E, Nilubol N. Thyroid cancer and nonsteroidal anti-inflammatory drug use: a pooled analysis of patients older than 40 years of age. Thyroid. 2015;25(12):1355–1362. doi: 10.1089/thy.2015.0198. [PMC free article] [PubMed] [CrossRef]
235. Reinau D, Surber C, Jick SS, Meier CR. Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer. Int J Cancer. 2015;137(1):144–153. doi: 10.1002/ijc.29357. [PubMed] [CrossRef]
236. Johannesdottir SA, Chang ET, Mehnert F, Schmidt M, Olesen AB, Sorensen HT. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer. 2012;118(19):4768–4776. doi: 10.1002/cncr.27406. [PubMed] [CrossRef]
237. Torti DC, Christensen BC, Storm CA, Fortuny J, Perry AE, Zens MS, Stukel T, Spencer SK, Nelson HH, Karagas MR. Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study. J Am Acad Dermatol. 2011;65(2):304–312. doi: 10.1016/j.jaad.2010.05.042. [PMC free article] [PubMed] [CrossRef]
238. Curiel-Lewandrowski C, Nijsten T, Gomez ML, Hollestein LM, Atkins MB, Stern RS. Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study. J Invest Dermatol. 2011;131(7):1460–1468. doi: 10.1038/jid.2011.58. [PubMed] [CrossRef]
239. Jeter JM, Bonner JD, Johnson TM, Gruber SB. Nonsteroidal anti-inflammatory drugs and risk of melanoma. J Skin Cancer. 2011;2011:598571. doi: 10.1155/2011/598571. [PMC free article] [PubMed] [CrossRef]
240. Asgari MM, Chren MM, Warton EM, Friedman GD, White E. Association between nonsteroidal anti-inflammatory drug use and cutaneous squamous cell carcinoma. Arch Dermatol. 2010;146(4):388–395. doi: 10.1001/archdermatol.2009.374. [PMC free article] [PubMed] [CrossRef]
241. Wysong A, Ally MS, Gamba CS, Desai M, Swetter SM, Seiffert-Sinha K, Sinha AA, Stefanick ML, Tang JY. Non-melanoma skin cancer and NSAID use in women with a history of skin cancer in the Women's Health Initiative. Prev Med. 2014;69:8–12. doi: 10.1016/j.ypmed.2014.08.024. [PubMed] [CrossRef]
242. Jeter JM, Han J, Martinez ME, Alberts DS, Qureshi AA, Feskanich D. Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses’ health study. Cancer Causes Control. 2012;23(9):1451–1461. doi: 10.1007/s10552-012-0019-6. [PMC free article] [PubMed] [CrossRef]
243. Cahoon EK, Rajaraman P, Alexander BH, Doody MM, Linet MS, Freedman DM. Use of nonsteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the United States radiologic technologists study. Int J Cancer. 2012;130(12):2939–2948. doi: 10.1002/ijc.26286. [PMC free article] [PubMed] [CrossRef]
244. Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst. 2008;100(13):967–971. doi: 10.1093/jnci/djn154. [PMC free article] [PubMed] [CrossRef]
245. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Catrina AI, Rosenquist R, Feltelius N, Sundstrom C, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701. doi: 10.1002/art.21675. [PubMed] [CrossRef]
246. Zhang YQ, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Risk of non-Hodgkin lymphoma and use of non-steroidal anti-inflammatory drugs. Cancer Detect Prev. 2006;30(1):99–101. doi: 10.1016/j.cdp.2005.12.002. [PubMed] [CrossRef]
247. Flick ED, Chan KA, Bracci PM, Holly EA. Use of nonsteroidal antinflammatory drugs and non-Hodgkin lymphoma: a population-based case-control study. Am J Epidemiol. 2006;164(5):497–504. doi: 10.1093/aje/kwj223. [PubMed] [CrossRef]
248. Baker JA, Weiss JR, Czuczman MS, Menezes RJ, Ambrosone CB, Moysich KB. Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control. 2005;16(3):301–308. doi: 10.1007/s10552-004-3074-9. [PubMed] [CrossRef]
249. Chang ET, Zheng TZ, Weir EG, Borowitz M, Mann RB, Spiegelman D, Mueller NE. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer I. 2004;96(4):305–315. doi: 10.1093/jnci/djh038. [PubMed] [CrossRef]
250. Zhang YW, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou KY, Flynn S, Tallini G, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004;15(4):419–428. doi: 10.1023/B:CACO.0000027506.55846.5d. [PubMed] [CrossRef]
251. Birmann BM, Giovannucci EL, Rosner BA, Colditz GA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and Nurses’ health study. Cancer Prev Res. 2014;7(1):33–41. doi: 10.1158/1940-6207.CAPR-13-0224. [PMC free article] [PubMed] [CrossRef]
252. Teras LR, Gapstur SM, Patel AV, Thun MJ, Diver WR, Zhai YS, Jacobs EJ. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of non-Hodgkin lymphoma. Cancer Epidem Biomark Prev. 2013;22(3):422–428. doi: 10.1158/1055-9965.EPI-12-1158. [PubMed] [CrossRef]
253. Chang ET, Froslev T, Sorensen HT, Pedersen L. A nationwide study of aspirin, other non-steroidal anti-inflammatory drugs, and Hodgkin lymphoma risk in Denmark. Br J Cancer. 2011;105(11):1776–1782. doi: 10.1038/bjc.2011.443. [PMC free article] [PubMed] [CrossRef]
254. Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective vitamins and lifestyle (VITAL) study. J Clin Oncol. 2011;29(17):2424–2431. doi: 10.1200/JCO.2011.34.6346. [PMC free article] [PubMed] [CrossRef]
255. Erber E, Lim U, Maskarinec G, Kolonel LN. Common immune-related risk factors and incident non-Hodgkin lymphoma: the multiethnic cohort. Int J Cancer. 2009;125(6):1440–1445. doi: 10.1002/ijc.24456. [PMC free article] [PubMed] [CrossRef]
256. Cerhan JR, Anderson KE, Janney CA, Vachon CM, Witzig TE, Habermann TM. Association of aspirin and other non-steroidal anti-inflammatory drug use with incidence of non-Hodgkin lymphoma. Int J Cancer. 2003;106(5):784–788. doi: 10.1002/ijc.11311. [PubMed] [CrossRef]
257. Ross JA, Blair CK, Cerhan JR, Soler JT, Hirsch BA, Roesler MA, Higgins RR, Nguyen PL. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomark Prev. 2011;20(8):1741–1750. doi: 10.1158/1055-9965.EPI-11-0411. [PMC free article] [PubMed] [CrossRef]
258. Weiss JR, Baker JA, Baer MR, Menezes RJ, Nowell S, Moysich KB. Opposing effects of aspirin and acetaminophen use on risk of adult acute leukemia. Leuk Res. 2006;30(2):164–169. doi: 10.1016/j.leukres.2005.06.023. [PubMed] [CrossRef]
259. Kasum CM, Blair CK, Folsom AR, Ross JA. Non-steroidal anti-inflammatory drug use and risk of adult leukemia. Cancer Epidemiol Biomark Prev. 2003;12(6):534–537. [PubMed]
260. Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, et al. Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study. Neuroendocrinology. 2016;103(5):531–537. doi: 10.1159/000440884. [PubMed] [CrossRef]
Articles from BMC Cancer are provided here courtesy of BioMed Central
High frequency or high dose use of aspirin should be prescribed with caution because of their associations with increased lung and prostate cancer risk, respectively.
Front Oncol. 2021; 11: 690219.
Published online 2021 Jun 18. doi: 10.3389/fonc.2021.690219
PMCID: PMC8279749
PMID: 34277434
Aspirin Use and Common Cancer Risk: A Meta-Analysis of Cohort Studies and Randomized Controlled Trials
Abstract
Background
Whether aspirin use can decrease or increase cancer risk remains controversial. In this study, a meta-analysis of cohort studies and randomized controlled trials (RCTs) were conducted to evaluate the effect of aspirin use on common cancer risk.
Method
Medline and Embase databases were searched to identify relevant studies. Meta-analyses of cohort studies and RCTs were performed to assess the effect of aspirin use on the risk of colorectal, gastric, breast, prostate and lung cancer. Cochran Q test and the I square metric were calculated to detect potential heterogeneity among studies. Subgroup meta-analyses according to exposure categories (frequency and duration) and timing of aspirin use (whether aspirin was used before and after cancer diagnosis) were also performed. A dose-response analysis was carried out to evaluate and quantify the association between aspirin dose and cancer risk.
Results
A total of 88 cohort studies and seven RCTs were included in the final analysis. Meta-analyses of cohort studies revealed that regular aspirin use reduced the risk of colorectal cancer (CRC) (RR=0.85, 95%CI: 0.78-0.92), gastric cancer (RR=0.67, 95%CI: 0.52-0.87), breast cancer (RR=0.93, 95%CI: 0.87-0.99) and prostate cancer (RR=0.92, 95%CI: 0.86-0.98), but showed no association with lung cancer risk. Additionally, meta-analyses of RCTs showed that aspirin use had a protective effect on CRC risk (OR=0.74, 95%CI: 0.56-0.97). When combining evidence from meta-analyses of cohorts and RCTs, consistent evidence was found for the protective effect of aspirin use on CRC risk. Subgroup analysis showed that high frequency aspirin use was associated with increased lung cancer risk (RR=1.05, 95%CI: 1.01-1.09). Dose-response analysis revealed that high-dose aspirin use may increase prostate cancer risk.
Conclusions
This study provides evidence for low-dose aspirin use for the prevention of CRC, but not other common cancers. High frequency or high dose use of aspirin should be prescribed with caution because of their associations with increased lung and prostate cancer risk, respectively. Further studies are warranted to validate these findings and to find the minimum effective dose required for cancer prevention.
Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA
Gerelateerde artikelen
- lage dosis aspirine dagelijks versterkt bloedarmoede, verlaagt HB waarden en verlaagt ferretine waarden na langjarig gebruik in vergelijking met placebo bij ouderen van 70 plus
- Aspirine dagelijks vermindert kans op overlijden aan kanker, vooral bij vormen van spijsverteringskanker
- Aspirientje (75 - 100 mg. mg.) dagelijks geeft minder kans op overlijden aan enkele soorten kanker, maar effect is pas na minimaal 5 tot 10 jaar te merken.
- Aspirine voorkomt ontstaan van kwaadaardige darmpoliepen na 1 jaar maar geeft na vier jaar geen verschil
- Aspirine elke dag lijkt het risico op een recidief van borstkanker te verkleinen blijkt uit retropostpectieve studie. Artikel geplaatst 3 maart 2010 copy 1
- Aspirine kan verdere uitzaaiingen van vormen van kanker met het type adenocarcinomen voorkomen. Dit toont een grote meta analyse aan van gerandomiseerde studies, gepubliceerd in The Lancet copy 1
- Aspirine zou kanker in mond en keel waaronder slokdarmkanker kunnen voorkomen copy 1
- Algemene informatie preventie
Plaats een reactie ...
Reageer op "Aspirine ter voorkoming van kanker of een recidief van kanker: een overzicht van studies met aspirine copy 1"